SEARCH:   Advanced

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Thomis, D. C. Articles by Clackson, T. Search for Related Content PubMed PubMed Citation Articles by Thomis, D. C. Articles by Clackson, T. Related Collections Apoptosis Immunotherapy Gene Therapy Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 March 2001, Vol. 97, No. 5, pp. 1249-1257 GENE THERAPY A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease Daniel C. Thomis, Sarah Marktel, Chiara Bonini, Catia Traversari, Michael Gilman, Claudio Bordignon, and Tim Clackson From ARIAD Gene Therapeutics, Cambridge, MA, and San Raffaele Telethon Institute for Gene Therapy and Cancer Immunotherapy and Gene Therapy Program, Istituto Scientifico H. S. Raffaele, Milan, Italy. Graft-versus-host disease (GVHD) is a major complication of allogeneic bone marrow transplantation. One strategy to treat GVHD is to equip donor T cells with a conditional suicide mechanism that can be triggered when GVHD occurs. The herpes simplex virus thymidine kinase (HSV-tk)/ganciclovir system used clinically has several limitations, including immunogenicity and cell cycle dependence. An alternative switch based on chemically inducible apoptosis was designed and evaluated. A chimeric human protein was expressed comprising an extracellular marker (LNGFR), the Fas intracellular domain, and 2 copies of an FK506-binding protein (FKBP). Primary human T lymphocytes retrovirally transduced with this construct could be purified to homogeneity using immunomagnetic beads. Genetic integrity of the construct was ensured by redesigning repetitive sequences. Transduced T cells behaved indistinguishably from untransduced cells, retaining the ability to mount a specific antiallogeneic immune response. However, they rapidly underwent apoptosis with the addition of subnanomolar concentrations of AP1903, a bivalent "dimerizer" drug that binds FKBP and induces Fas cross-linking. A single 2-hour treatment eliminated approximately 80% of T cells, and multiple exposures induced further apoptosis. T cells were eliminated regardless of their proliferation state, suggesting that the AP1903/Fas system, which contains only human components, is a promising alternative to HSV-tk for treating GVHD. © 2001 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: H. J. Pegram, J. T. Jackson, M. J. Smyth, M. H. Kershaw, and P. K. Darcy Adoptive Transfer of Gene-Modified Primary NK Cells Can Specifically Inhibit Tumor Progression In Vivo J. Immunol., September 1, 2008; 181(5): 3449 - 3455. [Abstract] [Full Text] [PDF] E. Kieback, J. Charo, D. Sommermeyer, T. Blankenstein, and W. Uckert A safeguard eliminates T cell receptor gene-modified autoreactive T cells after adoptive transfer PNAS, January 15, 2008; 105(2): 623 - 628. [Abstract] [Full Text] [PDF] M. Deschamps, P. Mercier-Lethondal, J. M. Certoux, C. Henry, B. Lioure, C. Pagneux, J. Y. Cahn, E. Deconinck, E. Robinet, P. Tiberghien, et al. Deletions within the HSV-tk transgene in long-lasting circulating gene-modified T cells infused with a hematopoietic graft Blood, December 1, 2007; 110(12): 3842 - 3852. [Abstract] [Full Text] [PDF] C. Traversari, S. Marktel, Z. Magnani, P. Mangia, V. Russo, F. Ciceri, C. Bonini, and C. Bordignon The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies Blood, June 1, 2007; 109(11): 4708 - 4715. [Abstract] [Full Text] [PDF] V. Ponomarev, M. Doubrovin, A. Shavrin, I. Serganova, T. Beresten, L. Ageyeva, C. Cai, J. Balatoni, M. Alauddin, and J. Gelovani A Human-Derived Reporter Gene for Noninvasive Imaging in Humans: Mitochondrial Thymidine Kinase Type 2 J. Nucl. Med., May 1, 2007; 48(5): 819 - 826. [Abstract] [Full Text] [PDF] T. Clackson Translational Research in Academia and Industry Experimental Biology and Medicine, December 1, 2006; 231(11): 1685 - 1689. [Abstract] [Full Text] [PDF] J. E. Qualls, A. M. Kaplan, N. van Rooijen, and D. A. Cohen Suppression of experimental colitis by intestinal mononuclear phagocytes J. Leukoc. Biol., October 1, 2006; 80(4): 802 - 815. [Abstract] [Full Text] [PDF] C. Berger, M. E. Flowers, E. H. Warren, and S. R. Riddell Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation Blood, March 15, 2006; 107(6): 2294 - 2302. [Abstract] [Full Text] [PDF] M. Moeller, N. M. Haynes, M. H. Kershaw, J. T. Jackson, M. W. L. Teng, S. E. Street, L. Cerutti, S. M. Jane, J. A. Trapani, M. J. Smyth, et al. Adoptive transfer of gene-engineered CD4+ helper T cells induces potent primary and secondary tumor rejection Blood, November 1, 2005; 106(9): 2995 - 3003. [Abstract] [Full Text] [PDF] T. Zhang, B. A. Lemoi, and C. L. Sentman Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy Blood, September 1, 2005; 106(5): 1544 - 1551. [Abstract] [Full Text] [PDF] K. C. Straathof, M. A. Pule, P. Yotnda, G. Dotti, E. F. Vanin, M. K. Brenner, H. E. Heslop, D. M. Spencer, and C. M. Rooney An inducible caspase 9 safety switch for T-cell therapy Blood, June 1, 2005; 105(11): 4247 - 4254. [Abstract] [Full Text] [PDF] S. H. Burnett, E. J. Kershen, J. Zhang, L. Zeng, S. C. Straley, A. M. Kaplan, and D. A. Cohen Conditional macrophage ablation in transgenic mice expressing a Fas-based suicide gene J. Leukoc. Biol., April 1, 2004; 75(4): 612 - 623. [Abstract] [Full Text] [PDF] K. C. Straathof and H. E. Heslop Dimerize and die Blood, February 15, 2004; 103(4): 1177 - 1178. [Full Text] [PDF] C. Berger, C. A. Blau, M.-L. Huang, J. D. Iuliucci, D. C. Dalgarno, J. Gaschet, S. Heimfeld, T. Clackson, and S. R. Riddell Pharmacologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate model Blood, February 15, 2004; 103(4): 1261 - 1269. [Abstract] [Full Text] [PDF] H.-J. Kolb, C. Schmid, A. J. Barrett, and D. J. Schendel Graft-versus-leukemia reactions in allogeneic chimeras Blood, February 1, 2004; 103(3): 767 - 776. [Abstract] [Full Text] [PDF] J. D. Roback, M. S. Hossain, L. Lezhava, J. W. Gorechlad, S. A. Alexander, D. L. Jaye, S. Mittelstaedt, S. Talib, J. E. Hearst, C. D. Hillyer, et al. Allogeneic T Cells Treated with Amotosalen Prevent Lethal Cytomegalovirus Disease without Producing Graft-versus-Host Disease Following Bone Marrow Transplantation J. Immunol., December 1, 2003; 171(11): 6023 - 6031. [Abstract] [Full Text] [PDF] R. Greil, G. Anether, K. Johrer, and I. Tinhofer Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: pathways, targets, and therapeutic tools J. Leukoc. Biol., September 1, 2003; 74(3): 311 - 330. [Abstract] [Full Text] [PDF] S. Marktel, Z. Magnani, F. Ciceri, S. Cazzaniga, S. R. Riddell, C. Traversari, C. Bordignon, and C. Bonini Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation Blood, February 15, 2003; 101(4): 1290 - 1298. [Abstract] [Full Text] [PDF] L. J. N. Cooper, M. S. Topp, L. M. Serrano, S. Gonzalez, W.-C. Chang, A. Naranjo, C. Wright, L. Popplewell, A. Raubitschek, S. J. Forman, et al. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect Blood, February 15, 2003; 101(4): 1637 - 1644. [Abstract] [Full Text] [PDF] K. C.M. Straathof, C. M. Bollard, C. M. Rooney, and H. E. Heslop Immunotherapy for Epstein-Barr Virus-Associated Cancers in Children Oncologist, February 1, 2003; 8(1): 83 - 98. [Abstract] [Full Text] [PDF] C. Berger, C. A. Blau, T. Clackson, S. R. Riddell, and S. Heimfeld CD28 costimulation and immunoaffinity-based selection efficiently generate primary gene-modified T cells for adoptive immunotherapy Blood, January 15, 2003; 101(2): 476 - 484. [Abstract] [Full Text] [PDF] H. E. Heslop, F. K. Stevenson, and J. J. Molldrem Immunotherapy of Hematologic Malignancy Hematology, January 1, 2003; 2003(1): 331 - 349. [Abstract] [Full Text] [PDF] X. Xie, X. Zhao, Y. Liu, J. Zhang, R. J. Matusik, K. M. Slawin, and D. M. Spencer Adenovirus-mediated Tissue-targeted Expression of a Caspase-9-based Artificial Death Switch for the Treatment of Prostate Cancer Cancer Res., September 1, 2001; 61(18): 6795 - 6804. [Abstract] [Full Text] [PDF] T. Neff and C. A. Blau Pharmacologically regulated cell therapy Blood, May 1, 2001; 97(9): 2535 - 2540. [Full Text] [PDF] R. F. Storb, R. Champlin, S. R. Riddell, M. Murata, S. Bryant, and E. H. Warren Non-Myeloablative Transplants for Malignant Disease Hematology, January 1, 2001; 2001(1): 375 - 391. [Abstract] [Full Text] [PDF]

	Copyright © 2001 by American Society of Hematology         Online ISSN: 1528-0020